NCT02349412 · STUDY IN CONTEXT

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Fam

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Higher scores on FACT-G indicate better QOL.

Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.

→

secondary · POSTED

Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-24 was calculated by subtracting the baseline scores from the scores at week-24. Higher scores on FACT-G indicate better QOL.

Only participants with available data on the individual study measure at baseline and 24 weeks were included in the analysis.

→

secondary · POSTED

Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Depression on a 0-21 scale, with lower scores corresponding to lower depression and higher scores corresponding to higher depression. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Depression indicate less depression symptoms.

Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.

→

secondary · POSTED

Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Anxiety on a 0-21 scale, with lower scores corresponding to lower anxiety and higher scores corresponding to higher anxiety. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Anxiety indicate less anxiety symptoms.

Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.

→

secondary · POSTED

Prognostic Understanding at Week-12 as measured by Prognosis and Treatment Perceptions Questionnaire: "Have you and your oncologist discussed any particular wishes about the care you would want to receive if you were dying?" responses at Week-12 are reported below.

Only participants with available data on the individual study measure at week 12 were included in the analysis.

→

secondary · NOT_POSTED

Change in QOL on the SF-36 Over Time

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

FACT · Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G)

Score direction: Higher is better, according to the source. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-gastric-cancer
nct id: NCT02349412
qol key: qol-0000
source section id: NCT02349412-om-0000
source outcome index: 0
instrument: FACT
instrument basis: matched 'fact-g' in the study's own wording
scale title: Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
measure definition: Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Higher scores on FACT-G indicate better QOL.
time frame: Up to 12 weeks
analysis role: primary
reporting status: POSTED
higher is better: 1
direction quote: higher scores corresponding to better
population note: Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

FACT · Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G)

Score direction: Higher is better, according to the source. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-gastric-cancer
nct id: NCT02349412
qol key: qol-0001
source section id: NCT02349412-om-0001
source outcome index: 1
instrument: FACT
instrument basis: matched 'fact-g' in the study's own wording
scale title: Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
measure definition: Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-24 was calculated by subtracting the baseline scores from the scores at week-24. Higher scores on FACT-G indicate better QOL.
time frame: Up to 24 weeks
analysis role: secondary
reporting status: POSTED
higher is better: 1
direction quote: higher scores corresponding to better
population note: Only participants with available data on the individual study measure at baseline and 24 weeks were included in the analysis.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

Unnamed quality-of-life measure · Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-gastric-cancer
nct id: NCT02349412
qol key: qol-0002
source section id: NCT02349412-om-0002
source outcome index: 2
instrument: Unnamed quality-of-life measure
instrument basis: matched 'quality of life' in the study's own wording
scale title: Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression
measure definition: Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Depression on a 0-21 scale, with lower scores corresponding to lower depression and higher scores corresponding to higher depression. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Depression indicate less depression symptoms.
time frame: Up to 12 weeks
analysis role: secondary
reporting status: POSTED
higher is better: Source null
direction quote: Source null
population note: Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

Unnamed quality-of-life measure · Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-gastric-cancer
nct id: NCT02349412
qol key: qol-0003
source section id: NCT02349412-om-0003
source outcome index: 3
instrument: Unnamed quality-of-life measure
instrument basis: matched 'quality of life' in the study's own wording
scale title: Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety
measure definition: Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Anxiety on a 0-21 scale, with lower scores corresponding to lower anxiety and higher scores corresponding to higher anxiety. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Anxiety indicate less anxiety symptoms.
time frame: Up to 12 weeks
analysis role: secondary
reporting status: POSTED
higher is better: Source null
direction quote: Source null
population note: Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

SF-36 / SF-12 · Change in QOL on the SF-36 Over Time

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-gastric-cancer
nct id: NCT02349412
qol key: qol-0005
source section id: NCT02349412-om-0005
source outcome index: 5
instrument: SF-36 / SF-12
instrument basis: matched 'sf-36' in the study's own wording
scale title: Change in QOL on the SF-36 Over Time
measure definition: Source null
time frame: Up to 3 years
analysis role: secondary
reporting status: NOT_POSTED
higher is better: Source null
direction quote: Source null
population note: Source null
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-gastric-cancer
nct id: NCT02349412
trial label: Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Fam
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 2
qol Count: 5

outcomes

release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0000
source section id
NCT02349412-om-0000
source outcome index
0
endpoint
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
endpoint definition
Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Higher scores on FACT-G indicate better QOL.
time origin
Up to 12 weeks
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0001
source section id
NCT02349412-om-0001
source outcome index
1
endpoint
Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
endpoint definition
Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-24 was calculated by subtracting the baseline scores from the scores at week-24. Higher scores on FACT-G indicate better QOL.
time origin
Up to 24 weeks
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Only participants with available data on the individual study measure at baseline and 24 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0002
source section id
NCT02349412-om-0002
source outcome index
2
endpoint
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression
endpoint definition
Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Depression on a 0-21 scale, with lower scores corresponding to lower depression and higher scores corresponding to higher depression. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Depression indicate less depression symptoms.
time origin
Up to 12 weeks
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0003
source section id
NCT02349412-om-0003
source outcome index
3
endpoint
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety
endpoint definition
Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Anxiety on a 0-21 scale, with lower scores corresponding to lower anxiety and higher scores corresponding to higher anxiety. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Anxiety indicate less anxiety symptoms.
time origin
Up to 12 weeks
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0004
source section id
NCT02349412-om-0004
source outcome index
4
endpoint
Prognostic Understanding at Week-12 as Measured by "Have You and Your Oncologist Discussed Any Particular Wishes About the Care You Would Want to Receive if You Were Dying?" Question on the Prognosis and Treatment Perceptions Questionnaire
endpoint definition
Prognostic Understanding at Week-12 as measured by Prognosis and Treatment Perceptions Questionnaire: "Have you and your oncologist discussed any particular wishes about the care you would want to receive if you were dying?" responses at Week-12 are reported below.
time origin
Up to 12 weeks
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Only participants with available data on the individual study measure at week 12 were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0005
source section id
NCT02349412-om-0005
source outcome index
5
endpoint
Change in QOL on the SF-36 Over Time
endpoint definition
Change in QOL on the SF-36 Over Time
time origin
Up to 3 years
analysis role
secondary
reporting status
NOT_POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0000
arm key
OG000
arm label
Arm 1 (Early Palliative Care)
regimen
Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
analyzed count
92
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0000
arm key
OG001
arm label
Arm 2 (Usual Care)
regimen
Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
analyzed count
101
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0001
arm key
OG000
arm label
Arm 1 (Early Palliative Care)
regimen
Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
analyzed count
68
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0001
arm key
OG001
arm label
Arm 2 (Usual Care)
regimen
Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
analyzed count
80
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0001#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0002
arm key
OG000
arm label
Arm 1 (Early Palliative Care)
regimen
Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
analyzed count
100
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0002
arm key
OG001
arm label
Arm 2 (Usual Care)
regimen
Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
analyzed count
112
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0002#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0003
arm key
OG000
arm label
Arm 1 (Early Palliative Care)
regimen
Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
analyzed count
100
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0003
arm key
OG001
arm label
Arm 2 (Usual Care)
regimen
Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
analyzed count
111
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0003#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0004
arm key
OG000
arm label
Arm 1 (Early Palliative Care)
regimen
Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
analyzed count
99
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
outcome key
om-0004
arm key
OG001
arm label
Arm 2 (Usual Care)
regimen
Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
analyzed count
110
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02349412-om-0004#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
harm key
EG000
source section id
NCT02349412-ae
event group key
EG000
event group label
Arm 1 (Early Palliative Care)
serious affected
0
serious at risk
0
other affected
0
other at risk
0
frequency threshold
0
collection period
Adverse events were not collected for this study.
event definition
Adverse events were not collected for this study.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
harm key
EG001
source section id
NCT02349412-ae
event group key
EG001
event group label
Arm 2 (Usual Care)
serious affected
0
serious at risk
0
other affected
0
other at risk
0
frequency threshold
0
collection period
Adverse events were not collected for this study.
event definition
Adverse events were not collected for this study.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
qol key
qol-0000
source section id
NCT02349412-om-0000
source outcome index
0
instrument
FACT
instrument basis
matched 'fact-g' in the study's own wording
scale title
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
measure definition
Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Higher scores on FACT-G indicate better QOL.
time frame
Up to 12 weeks
analysis role
primary
reporting status
POSTED
higher is better
1
direction quote
higher scores corresponding to better
population note
Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
qol key
qol-0001
source section id
NCT02349412-om-0001
source outcome index
1
instrument
FACT
instrument basis
matched 'fact-g' in the study's own wording
scale title
Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
measure definition
Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-24 was calculated by subtracting the baseline scores from the scores at week-24. Higher scores on FACT-G indicate better QOL.
time frame
Up to 24 weeks
analysis role
secondary
reporting status
POSTED
higher is better
1
direction quote
higher scores corresponding to better
population note
Only participants with available data on the individual study measure at baseline and 24 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
qol key
qol-0002
source section id
NCT02349412-om-0002
source outcome index
2
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression
measure definition
Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Depression on a 0-21 scale, with lower scores corresponding to lower depression and higher scores corresponding to higher depression. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Depression indicate less depression symptoms.
time frame
Up to 12 weeks
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
qol key
qol-0003
source section id
NCT02349412-om-0003
source outcome index
3
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety
measure definition
Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Anxiety on a 0-21 scale, with lower scores corresponding to lower anxiety and higher scores corresponding to higher anxiety. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Lower scores on the HADS-Anxiety indicate less anxiety symptoms.
time frame
Up to 12 weeks
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Only participants with available data on the individual study measure at baseline and 12 weeks were included in the analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastric-cancer
nct id
NCT02349412
qol key
qol-0005
source section id
NCT02349412-om-0005
source outcome index
5
instrument
SF-36 / SF-12
instrument basis
matched 'sf-36' in the study's own wording
scale title
Change in QOL on the SF-36 Over Time
measure definition
Source null
time frame
Up to 3 years
analysis role
secondary
reporting status
NOT_POSTED
higher is better
Source null
direction quote
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

setting source links

Preserved source evidence · Not medical advice